BioSpace News Archive

Drug Development

Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Kite, a Gilead Company, announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T cell therapy.

June 1, 2019
·
6 min read
Drug Development

ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors

New Clinical Data Presented at the 2019 American Society of Clinical Oncology in Chicago, IL

June 1, 2019
·
3 min read
Drug Development

Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019

Intensity Therapeutics, Inc. announced positive preliminary results from the company’s ongoing Phase 1/2 clinical trial of its lead product candidate, INT230-6, in a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

June 1, 2019
·
5 min read
Job Trends

Expanded Rubraca® (Rucaparib) Data from Clovis Oncology’s ARIEL3 and TRITON2 Trials in Ovarian and Prostate Cancers to be Presented at 2019 ASCO Annual Meeting

Clovis Oncology, Inc. announced multiple datasets being presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, May 31 – June 4, 2019.

June 1, 2019
·
16 min read
Genetown

Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib

Blueprint Medicines Corporation announced data from the registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors and fourth-line GIST.

June 1, 2019
·
13 min read
Business

BioGENEius Challenge Announces 2019 Mentor of the Year Awardee

The Biotechnology Institute announced the winner of the Mentor of the Year Award, who will be recognized next week at the 2019 BIO International Convention in Philadelphia.

June 1, 2019
·
3 min read
Policy

Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

Veracyte, Inc. announced new data demonstrating the potential for its Afirma® Xpression Atlas (XA) genomic test to guide targeted treatment selection for patients with a rare but aggressive form of thyroid cancer concurrent with diagnosis by the company’s Afirma Genomic Sequencing Classifier (GSC).

June 1, 2019
·
6 min read
Pharm Country

Five-Year Survival Data for Merck’s KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer (NSCLC) from First KEYNOTE Trial at 2019 ASCO Annual Meeting

Longest Follow-Up Data for KEYTRUDA in Lung Cancer to Date Showed Five-Year Overall Survival Rate of 23.2% with KEYTRUDA in Treatment-Naïve Patients and 15.5% in Previously Treated Patients with Advanced NSCLC in KEYNOTE-001 Trial

June 1, 2019
·
36 min read
Drug Development

Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting

Nektar Therapeutics announced that biomarker and clinical data from PIVOT-02 is being presented at the 2019 American Society of Clinical Oncology Meeting in Chicago, Illinois.

June 1, 2019
·
7 min read
Drug Development

Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting

Moderna, Inc. announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors.

June 1, 2019
·
10 min read